Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery
Copyright © 2022. Published by Elsevier Inc..
Colorectal cancer (CRC) is the third most common cancer with the second most frequent cause of death worldwide. One fourth to one fifth of the CRC cases are detected at advance stage. Early detection of colorectal cancer might help in decreasing mortality and morbidity worldwide. CRC being a heterogeneous disease, new non-invasive approaches are needed to complement and improve the screening and management of CRC. Reliable and early detectable biomarkers would improve diagnosis, prognosis, therapeutic responses, and will enable the prediction of drug response and recurrence risk. Over the past decades molecular research has demonstrated the potentials of CTCs, ctDNAs, circulating mRNAs, ncRNAs, and exosomes as tumor biomarkers. Non-invasive screening approaches using fecal samples for identification of altered gut microbes in CRC is also gaining attention. Exosomes can be potential candidates that can be employed in the drug delivery system. Further, the integration of in vitro, in vivo and in silico models that involve CRC biomarkers will help to understand the interactions occurring at the cellular level. This review summarizes recent update on CRC biomarkers and their application along with the nanoparticles followed by the application of organoid culture in CRC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:99 |
|---|---|
| Enthalten in: |
Cellular signalling - 99(2022) vom: 20. Nov., Seite 110413 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sattar, Real Sumayya Abdul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 03.10.2022 Date Revised 24.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cellsig.2022.110413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344272133 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344272133 | ||
| 003 | DE-627 | ||
| 005 | 20231226022359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cellsig.2022.110413 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344272133 | ||
| 035 | |a (NLM)35907519 | ||
| 035 | |a (PII)S0898-6568(22)00175-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sattar, Real Sumayya Abdul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic and prognostic biomarkers in colorectal cancer and the potential role of exosomes in drug delivery |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.10.2022 | ||
| 500 | |a Date Revised 24.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Inc. | ||
| 520 | |a Colorectal cancer (CRC) is the third most common cancer with the second most frequent cause of death worldwide. One fourth to one fifth of the CRC cases are detected at advance stage. Early detection of colorectal cancer might help in decreasing mortality and morbidity worldwide. CRC being a heterogeneous disease, new non-invasive approaches are needed to complement and improve the screening and management of CRC. Reliable and early detectable biomarkers would improve diagnosis, prognosis, therapeutic responses, and will enable the prediction of drug response and recurrence risk. Over the past decades molecular research has demonstrated the potentials of CTCs, ctDNAs, circulating mRNAs, ncRNAs, and exosomes as tumor biomarkers. Non-invasive screening approaches using fecal samples for identification of altered gut microbes in CRC is also gaining attention. Exosomes can be potential candidates that can be employed in the drug delivery system. Further, the integration of in vitro, in vivo and in silico models that involve CRC biomarkers will help to understand the interactions occurring at the cellular level. This review summarizes recent update on CRC biomarkers and their application along with the nanoparticles followed by the application of organoid culture in CRC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a CRC | |
| 650 | 4 | |a Non-invasive | |
| 650 | 4 | |a Organoids | |
| 650 | 4 | |a Screening | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Verma, Renu |e verfasserin |4 aut | |
| 700 | 1 | |a Nimisha |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Arun |e verfasserin |4 aut | |
| 700 | 1 | |a Dar, Ghulam Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Apurva |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, Abhay Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kumari, Indu |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Ejaj |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Asgar |e verfasserin |4 aut | |
| 700 | 1 | |a Mahajan, Bhawna |e verfasserin |4 aut | |
| 700 | 1 | |a Saluja, Sundeep Singh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cellular signalling |d 1993 |g 99(2022) vom: 20. Nov., Seite 110413 |w (DE-627)NLM012637653 |x 1873-3913 |7 nnns |
| 773 | 1 | 8 | |g volume:99 |g year:2022 |g day:20 |g month:11 |g pages:110413 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cellsig.2022.110413 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 99 |j 2022 |b 20 |c 11 |h 110413 | ||